164 related articles for article (PubMed ID: 25444817)
1. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
[TBL] [Abstract][Full Text] [Related]
2. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
3. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
4. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
[TBL] [Abstract][Full Text] [Related]
5. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
6. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
7. 4-1BBL costimulation retrieves CD28 expression in activated T cells.
Habib-Agahi M; Jaberipour M; Searle PF
Cell Immunol; 2009; 256(1-2):39-46. PubMed ID: 19217084
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner.
Srivastava AK; Sharma RK; Yolcu ES; Ulker V; MacLeod K; Dinc G; Shirwan H
PLoS One; 2012; 7(11):e48463. PubMed ID: 23144888
[TBL] [Abstract][Full Text] [Related]
9. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
Powell KL; Stephens AS; Ralph SJ
Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
[TBL] [Abstract][Full Text] [Related]
11. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
13. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
Yan X; Johnson BD; Orentas RJ
J Immunol; 2008 Oct; 181(7):4621-31. PubMed ID: 18802064
[TBL] [Abstract][Full Text] [Related]
14. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors.
Sharma RK; Elpek KG; Yolcu ES; Schabowsky RH; Zhao H; Bandura-Morgan L; Shirwan H
Cancer Res; 2009 May; 69(10):4319-26. PubMed ID: 19435920
[TBL] [Abstract][Full Text] [Related]
15. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
17. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo.
Dawicki W; Watts TH
Eur J Immunol; 2004 Mar; 34(3):743-751. PubMed ID: 14991604
[TBL] [Abstract][Full Text] [Related]
18. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
Li Q; Ai J; Song Z; Liu J; Shan B
Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562
[TBL] [Abstract][Full Text] [Related]
20. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
